Abstracts
Résumé
L'activité de l'ostéoclaste, cellule en charge de la résorption osseuse, est soumise à différents facteurs de régulation. Parmi eux, ceux issus de la matrice, en particulier les minéraux qui en sont libérés, comme le calcium, sont déterminants. Nous avons montré que la variation de concentration en calcium dans le milieu régulait l'activité de résorption et la durée de vie des ostéoclastes. Le développement d'une nouvelle thérapeutique, le ranélate de strontium, a montré des effets cliniques très intéressants reposant sur une stimulation des activités de formation de l'os par les ostéoblastes et une modulation des activités de résorption osseuse. Sur la base de nos connaissances de la physiologie de l'ostéoclaste, en particulier des voies de signalisation calcique, et de la maîtrise de différents modèles cellulaires ostéoclastiques, une collaboration logique s'est créée entre notre laboratoire et Servier afin d'approfondir les mécanismes à l'origine des effets du ranélate de strontium sur les ostéoclastes. En quelques années, cette collaboration s'est progressivement enrichie d'autres intervenants scientifiques afin de mieux éclairer ces mécanismes. Il a ainsi été montré que le strontium interagissait probablement avec le récepteur sensible au calcium et que les voies de signalisation intracellulaires activées par le calcium et le ranélate de strontium via ce récepteur étaient différentes. Dans le cadre de cette coopération avec Servier, des échanges avec d'autres laboratoires universitaires ont été initiés, telles que la mise en commun de techniques et de connaissances. Ainsi, il a été possible de confirmer la présence du récepteur sensible au calcium sur les ostéoclastes et de montrer son rôle dans les effets du ranélate de strontium sur l'ostéoclaste.
Summary
The activity of the osteoclast, the cell responsible for bone resorption, is subjected to different regulation factors. Amongst these, those issued from the matrix, particularly released minerals such as calcium, are determinants. We have shown that variations in calcium concentration in the medium regulates resorption activity and duration of the osteoclast lifespan. The development of a new therapeutic agent, strontium ranelate, has shown very interesting clinical effects reliant on the stimulation of bone formation activity by osteoblasts and modulation of bone resorption activity. From our knowledge regarding osteoclast physiology, in particular calcium signaling pathways, and the control of different osteoclast cellular models, a consequent collaboration was formed between our laboratory and Servier in order to elaborate on the effects of strontium ranelate on the osteoclast. In several years, this collaboration has been further enriched by other collaborators in order to better understand this mechanism. It has also been shown that strontium likely interacts with the calcium-sensing receptor and that the pathways of intracellular signaling pathways activated by calcium and strontium ranelate via this receptor are different. In fact, within the scope of this collaboration with Servier, exchanges with other academic laboratories were initiated and collaboration on numerous techniques became possible. Then, it has been possible to confirm the presence of the calcium-sensing receptor on the osteoclasts and to demonstrate its role in the molecular events associated with strontium ranelate's effects on the osteoclast.
Appendices
Références
- 1. Organisation Mondiale de la Santé. Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva : WHO, 1998.
- 2. Baudoin C, Fardellone P, Bean K, et al. Clinical outcomes and mortality after hip fracture : a 2-year follow-up study. Bone 1996 ; 18 (suppl 3) : S149-57.
- 3. McCreadie BR, Goldstein SA. Biomechanics of fracture : Is bone mineral density sufficient to assess risk ? J Bone Miner Res 2000 ; 15 : 2305-8.
- 4. Nguyen TV, Eisman JA. Genetics of fracture : challenges and opportunities. J Bone Miner Res 2000 ; 15 : 1253-6.
- 5. Ralston SH. The genetics of osteoporosis. Bone 1999 ; 25 : 85-6.
- 6. Harvey N, Cooper C. Determinants of fracture risk in osteoporosis. Curr Rheumatol Rep 2003 ; 5 : 75-81.
- 7. Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 2002 ; 16 : 795-806.
- 8. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002 ; 450 : 11-7.
- 9. Takahashi N, Sasaki T, Tsouderos Y, Suda T. S12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003 ; 18 : 1082-7.
- 10. Canalis E, Hott M, Deloffre P, et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996 ; 18 : 517-23.
- 11. Chattopadhyay N, Yano S, Tfelt-Hansen J, et al. Strontium ranelate promotes chemotaxis, stimulates proliferation and induces genes involved in the differentiation of rat primary osteoblasts. Bone 2005 ; 36 : S400.
- 12. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004 ; 350 : 459-68.
- 13. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis : treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005 ; 90 : 2916-822.
- 14. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrinol Rev 1999 ; 20 : 345-57.
- 15. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000 ; 289 : 1504-8.
- 16. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin : a novel secreted protein involved in the regulation of bone density. Cell 1997 ; 89 : 309-19.
- 17. Vaananen HK, Horton M. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 1995 ; 108 : 2729-32.
- 18. Manolagas SC. Birth and death of bone cells : basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocrinol Rev 2000 ; 21 : 115-37.
- 19. Silver IA, Murrills RJ, Etherington DJ. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res 1988 ; 175 : 266-76.
- 20. Lorget F, Kamel S, Mentaverri R, et al. High extracellular calcium concentrations directly stimulate osteoclast apoptosis. Biochem Biophys Res Commun 2000 ; 268 : 899-903.
- 21. Zaïdi M, Blair HC, Moonga BS, et al. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 2003 ; 18 :599-609.
- 22. Murphy MG, Cerchio K, Stoch SA, et al. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005 ; 90 : 2022-8.
- 23. Lorget F, Mentaverri R, Meddah B, et al. Evaluation of in vitro bone resorption : high-performance liquid chromatography measurement of the pyridinolines released in osteoclast cultures. Anal Biochem 2000 ; 284 : 375-81.
- 24. Kameda T, Mano H, Yuasa T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 1997 ; 186 : 489-95.
- 25. Wattel A, Kamel S, Mentaverri R, et al. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol 2003 ; 65 : 35-42.
- 26. Mentaverri R, Kamel S, Wattel A, et al. Regulation of bone resorption and osteoclast survival by nitric oxide : possible involvement of NMDA-receptor. J Cell Biochem 2003 ; 88 : 1145-56.
- 27. Wattel A, Kamel S, Prouillet C, et al. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NFkappa B and AP-1. J Cell Biochem 2004 ; 92 : 285-95.
- 28. Iotsova V, Caamano J, Loy J, et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997 ; 3 : 1285-9.
- 29. Grigoriadis AE, Wang ZQ, Cecchini MG, et al. c-Fos : a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994 ; 266 : 443-8.
- 30. Malgaroli A, Meldolesi J, Zallone AZ, et al. Control of cytosolic free calcium in rat and chicken osteoclasts. The role of extracellular calcium and calcitonin. J Biol Chem 1989 ; 264 :14342-7.
- 31. Datta HK, MacIntyre I, Zaidi M. The effect of extracellular calcium elevation on morphology and function of isolated rat osteoclasts. Biosci Rep 1989 ; 9 : 747-51.
- 32. Mentaverri R, Kamel S, Brazier M. Involvement of capacitive calcium entry and calcium store refilling in osteoclastic survival and bone resorption process. Cell Calcium 2003; 34 : 169-75.
- 33. Mentaverri R, Hurtel AS, Kamel S, et al. Strontium ranelate directly stimulates osteoclast apoptosis. Osteoporos Int 2004 ; 15 (suppl 1) : P345MO.
- 34. Mentaverri R, Hurtel AS, Wattel A, et al. Calcium-sensing receptor mediates strontium ranelate-induced osteoclasts apoptosis. Bone 2005 ; 36 : S403.